Non-specific Endonuclease Market By Grade (Research Grade, GMP Grade), By Product Type (Standard Non-specific Endonucleases, Salt-Tolerant Non-specific Endonucleases), By Form (Liquid, Lyophilized), By Application (Viral Vector Manufacturing, Vaccine Manufacturing, Recombinant Protein and Biologics Production, Cell and Gene Therapy Manufacturing, Research and Cell Lysis), By End User (Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations [CDMOs/CMOs], Academic and Research Institutes, Diagnostic and Clinical Laboratories), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Non-specific Endonuclease Market: GMP-Grade Enzymes Become Critical Inputs for Advanced Biomanufacturing

The Global Non-specific Endonuclease Market was valued at an estimated USD 0.42 billion in 2025 and is projected to reach USD 0.82 billion by 2032, expanding at a CAGR of 10.0% during 2026–2032.

 

The non-specific endonuclease market covers enzymes that break down DNA and RNA without needing a specific sequence. These enzymes are used in research and, increasingly, in biomanufacturing where product quality is critical. Key types include Benzonase, DNase I, micrococcal nuclease, and salt-active nucleases. They are widely used to remove nucleic acid contamination, reduce sample viscosity, and improve downstream purification steps such as filtration and chromatography.

 

The only FDA-approved therapeutic non-specific endonuclease is Pulmozyme (dornase alfa) from Genentech, a recombinant human DNase I used as an inhaled treatment for cystic fibrosis. It works by breaking down extracellular DNA in airway mucus, reducing viscosity, improving mucus clearance, and lowering infection risk. The standard dose is 2.5 mg inhaled once daily via nebulizer.

 

Beyond this single approved drug, there is no significant clinical pipeline for systemic non-specific endonuclease therapies. Instead, these enzymes are primarily used as GMP bioprocessing tools—typically recombinant or Serratia-derived nucleases—to degrade host-cell DNA and reduce viscosity during manufacturing of viral vectors, vaccines, and biologics. Many of these industrial enzymes are supported by FDA Drug Master Files (DMFs) to ensure regulatory compliance in clinical and commercial production.

 

The Structural Evolution of Demand Across Product Grades, Technologies, and Applications

By Grade

Research-grade enzymes accounted for the larger 56.0% share of the market in 2025, representing approximately USD 0.235 billion. Their use across molecular biology, cell lysis, nucleic-acid preparation, protein research and early-stage process development supports broad purchasing volumes. The segment is projected to reach USD 0.394 billion by 2032 at a CAGR of 7.6%.

GMP-grade non-specific endonucleases represented 44.0% of the market and generated approximately USD 0.185 billion in 2025. The segment is projected to expand at a CAGR of 12.7% and reach USD 0.426 billion by 2032, overtaking research-grade products in revenue by the end of the forecast period.

The higher growth rate reflects increasing use in clinical and commercial manufacturing environments where manufacturers require documented production controls, batch consistency, impurity profiles, traceability, regulatory support and formal change-notification procedures. Products supported by Drug Master Files, GMP manufacturing documentation and validated residual-enzyme detection methods are positioned to command higher value than general research reagents.

 

By Product Type

Standard non-specific endonucleases dominated the market with a 72.0% share and revenue of approximately USD 0.302 billion in 2025. Their established use across research, vaccine production, recombinant protein processing and conventional biomanufacturing supports continued revenue growth. The segment is projected to reach USD 0.517 billion by 2032 at a CAGR of 8.0%.

Salt-tolerant non-specific endonucleases accounted for a smaller 28.0% share and approximately USD 0.118 billion in 2025 but are projected to record the faster CAGR of 14.5%. The segment is expected to reach USD 0.303 billion by 2032.

Salt-tolerant products address a key process constraint, as conventional nuclease activity decreases at elevated ionic strength. Enzymes that retain activity under physiological or high-salt conditions help reduce dilution needs, buffer usage, vessel volume pressure, and additional processing steps. Their adoption is closely tied to viral-vector workflows, where salt is used to control aggregation, maintain vector stability, and optimize downstream purification.

 

By Form

Liquid formulations held 81.0% of the market in 2025, equivalent to approximately USD 0.340 billion. Liquid nucleases are widely used because they can be dosed directly into cell lysates, culture harvests and downstream processing vessels without a separate reconstitution step. The segment is projected to reach USD 0.640 billion by 2032 at a CAGR of 9.4%.

Lyophilized products represented 19.0% of the market and generated approximately USD 0.080 billion in 2025. The segment is projected to expand at a CAGR of 12.4% and reach USD 0.180 billion by 2032.

The faster growth of lyophilized formulations reflects demand for products with extended storage stability, reduced cold-chain exposure and greater suitability for international distribution or lower-frequency laboratory use. However, liquid formulations will remain dominant because large-scale bioprocessing operations generally prioritize immediate dosing, simplified handling and integration into established manufacturing protocols.

 

By Application

Viral-vector manufacturing was the largest application segment in 2025, accounting for 31.0% of the market and approximately USD 0.130 billion. The segment is projected to reach USD 0.279 billion by 2032 at a CAGR of 11.5%. Nucleases are used during adenoviral, adeno-associated viral, lentiviral, retroviral and other vector manufacturing processes to reduce host-cell and plasmid nucleic-acid contamination and improve downstream processing.

Vaccine manufacturing represented 22.0% of the market and generated approximately USD 0.092 billion in 2025. The segment is projected to reach USD 0.164 billion by 2032 at a CAGR of 8.5%. Continued demand is supported by the use of cell substrates and biological production systems that require documented residual-DNA degradation and removal.

Recombinant protein and biologics production accounted for 18.0% of the market and approximately USD 0.076 billion in 2025. The segment is projected to reach USD 0.123 billion by 2032 at a CAGR of 7.2%. Endonucleases are used to reduce lysate viscosity, improve clarification and support efficient filtration and chromatography during protein purification.

Cell and gene therapy manufacturing represented 17.0% of the market in 2025, equivalent to approximately USD 0.071 billion. It is projected to record the fastest application CAGR of 14.2% and reach USD 0.180 billion by 2032. Growth reflects the expanding number of clinical and commercial advanced-therapy programmes and their need for GMP-grade ancillary materials, validated impurity controls and scalable vector-processing workflows.

Research and cell lysis accounted for 12.0% of the market and approximately USD 0.050 billion in 2025. The segment is projected to reach USD 0.074 billion by 2032 at a CAGR of 5.6%. It remains an important volume market but faces lower regulatory barriers, broader product substitution and stronger price competition than clinical manufacturing applications.

Viral-vector and cell-and-gene-therapy applications receive the strongest growth allocations because non-specific endonucleases are used to reduce residual host-cell and plasmid nucleic acids during downstream processing. Commercial manufacturing workflows also increasingly require documented GMP-grade raw materials and residual-DNA controls.

 

By End User

Pharmaceutical and biotechnology companies accounted for the largest end-user share of 46.0% and generated approximately USD 0.193 billion in 2025. The segment is projected to reach USD 0.361 billion by 2032 at a CAGR of 9.3%. Demand includes internal research, process development, pilot manufacturing, validation activities and commercial biologics or advanced-therapy production.

Contract development and manufacturing organizations accounted for 27.0% of the market and approximately USD 0.113 billion in 2025. The segment is projected to record the fastest end-user CAGR of 13.7%, reaching USD 0.279 billion by 2032.

CDMOs and CMOs frequently operate multiple customer programmes across different vector types, cell lines, production scales and regulatory stages. This creates demand for nuclease products that can be qualified across platforms and supplied consistently from development batches through commercial production. Supplier relationships with CDMOs can also create access to multiple therapy developers through a single manufacturing account.

Academic and research institutes represented 19.0% of the market and generated approximately USD 0.080 billion in 2025. The segment is projected to reach USD 0.131 billion by 2032 at a CAGR of 7.4%. University laboratories, public research institutions and translational manufacturing centres support recurring demand for research-grade enzymes and early-stage process-development materials.

Diagnostic and clinical laboratories accounted for 8.0% of the market and approximately USD 0.034 billion in 2025. The segment is projected to reach USD 0.049 billion by 2032 at a CAGR of 5.6%. Demand is comparatively smaller and is concentrated in sample preparation, nucleic-acid removal, protein analysis and specialised laboratory workflows.

 

Residual-DNA Control Is Turning Nucleases into Validated Process Materials

Regulatory requirements around residual DNA are a key reason non-specific endonucleases are now treated as controlled manufacturing inputs rather than simple lab reagents. WHO has highlighted potential risks from leftover cellular DNA in vaccines, including theoretical genetic integration and transmission of latent agents, which drives strict expectations for DNA degradation and removal across biologics manufacturing.

FDA gene-therapy CMC guidance similarly requires detailed control of manufacturing inputs to ensure product safety, quality, and purity, and gaps in CMC data can result in clinical holds. As a result, nucleases used in viral-vector purification must be fully documented, and any change in supplier, grade, or process conditions can trigger regulatory reassessment.

This has translated into concrete procurement standards. For example, a National Cancer Institute GMP lentiviral vector specification required residual Benzonase levels below 0.2 ng/mL (measured by ELISA), alongside sterility, endotoxin, and replication-competent virus testing. These requirements are also increasing demand for supporting tools such as validated residual-enzyme assays and regulatory documentation packages.

 

Viral-Vector Manufacturing Is the Main Commercial Growth Engine

Viral-vector manufacturing is the largest application for non-specific endonucleases because it generates high levels of host-cell and plasmid DNA that must be removed while preserving sensitive viral particles. FDA has approved nearly 50 cell and gene therapy products over the past decade (as of 2026), and each new programme adds demand for process development, validation, and routine GMP production—driving repeated enzyme use across manufacturing stages.

In lentiviral production, enzymes like Benzonase are added after transfection to break down residual plasmid DNA before purification. This step improves viscosity control, filtration efficiency, chromatography performance, and overall DNA clearance, making nuclease choice important for process yield and consistency, not just cost.

Similar requirements exist for AAV, retroviral vectors, oncolytic viruses, and viral vaccines, but each process has different operating conditions. As a result, manufacturers are increasingly testing nucleases under real process settings (salt, pH, temperature, and cell density), supporting a shift toward engineered, application-specific enzymes rather than general-purpose products.

Demand is further supported by public and academic manufacturing initiatives. For example, the U.S. National Cancer Institute operates GMP manufacturing facilities for cell and gene therapies, increasing procurement of qualified enzymes and other GMP-grade raw materials even for early-stage and clinical research programs.

 

Salt Tolerance Is Reshaping Product Competition

Salt concentration is now a key factor in the non-specific endonuclease market. Many standard enzymes lose activity in higher-salt conditions, while viral-vector manufacturers often use salt to improve stability and reduce aggregation. If enzymes are not salt-tolerant, manufacturers may need extra dilution, buffer exchange, or higher enzyme doses, which increases processing time and cost.

To address this, suppliers are developing salt-active GMP enzymes. In 2025, ArcticZymes launched M-SAN HQ GMP for use at around 150 mM salt, designed for direct use in viral-vector processes without extra buffer steps. Similarly, Kerry’s c-LEcta introduced Denarase High Salt GMP, which remains active above 150 mM salt and is offered in both development and GMP grades to support scale-up.

New England Biolabs also offers a Salt Active Nuclease GMP grade with high activity across a wide salt range, including up to 500 mM, and strong purity and low endotoxin levels. Overall, competition is shifting from basic enzyme activity toward better performance under real manufacturing conditions and stronger regulatory documentation.

 

GMP Grade, Master Files and Residual-Enzyme Testing Create Premium Value

The market is separating into research-grade products and higher-value materials intended for clinical or commercial manufacturing. Research-grade enzymes are purchased mainly on activity, purity, package size and price. GMP-oriented purchasing involves supplier audits, manufacturing consistency, animal-origin statements, endotoxin and bioburden controls, stability data, change-notification procedures, regulatory support and residual-enzyme assays.

Merck retains a strong incumbent position through the Benzonase portfolio. The company supplies multiple purity grades and package sizes, including products manufactured under GMP with an EMPROVE documentation package and an FDA Bulk Biological Master File. Merck reports that Benzonase cleaves DNA and RNA into fragments containing fewer than eight base pairs and has more than 30 years of use in biopharmaceutical production. Its broad installed base reduces process-change risk for manufacturers with established regulatory filings.

ArcticZymes has used regulatory documentation to reduce entry barriers against established suppliers. Its Type II Drug Master File for SAN HQ GMP was accepted by FDA in September 2023 under Master File number 29754. The file covers manufacturing, controls, packaging and storage and can be referenced by customers in INDs, BLAs and other submissions.

c-LEcta reports that the original Denarase product has been used in hundreds of clinical and commercial gene-therapy, cell-therapy and vaccine manufacturing processes since its 2012 launch. Its product history states that Denarase had reached more than 150 customers in over 30 countries by 2022 and was used in four commercial and more than 40 Phase I–III viral-vector processes. These are supplier disclosures rather than independently audited market totals, but they demonstrate the value of an enzyme’s regulatory and manufacturing history.

Residual-enzyme testing also creates an adjoining market for ELISA kits and analytical support. Manufacturers must demonstrate that a nuclease added during processing does not remain above an acceptable level in the final material. Suppliers offering matched enzymes and residual-detection kits can capture recurring analytical revenue while making method transfer and validation easier for customers.

 

Commercial Momentum Is Visible in Supplier Results

ArcticZymes is one of the clearest indicators of growth in this niche market. In Q2 2025, its biomanufacturing revenue reached NOK 18.1 million, up 52% year over year and accounting for 68% of total sales. Its M-SAN HQ enzyme was the top performer, growing 130% year over year, with early adoption from CDMOs integrating it into production workflows.

For full-year 2025, biomanufacturing revenue grew 23%, while GMP-grade sales rose about 106% in Q4 alone. In Q1 2026, total sales increased 36% to NOK 31.8 million, supported by repeat orders of M-SAN HQ and its ELISA kit from global CDMOs—showing strong customer retention after qualification.

Competition is also expanding. GenScript offers a GMP tag-free Benz-Neburase with high purity (≥99%) and very low endotoxin levels, targeting regulated manufacturing use. In contrast, Thermo Fisher’s Pierce Universal Nuclease remains focused on research applications such as cell lysis and protein workflows, highlighting the split between research-grade and GMP-grade demand.

 

Regional Demand Follows Advanced-Therapy Manufacturing Activity

North America leads the market with a 42.0% share, valued at approximately USD 0.176 billion in 2025, and is projected to reach USD 0.320 billion by 2032, growing at a CAGR of 8.9%. The region’s dominance is driven by its strong base of gene-therapy developers, CDMOs, and FDA-regulated manufacturing. FDA’s 2026 CMC guidance adds flexibility for cell and gene therapy development, but still requires strict quality and impurity-control standards, sustaining demand for GMP-grade nucleases.

Europe accounts for 29.0% of the market, representing approximately USD 0.122 billion in 2025, and is expected to reach USD 0.221 billion by 2032 at a CAGR of 8.9%. The region is supported by centralized EMA oversight of advanced therapies and a well-established enzyme manufacturing ecosystem. In 2025, ArcticZymes expanded its European reach through a distribution deal with Brenntag Specialties Pharma for SAN HQ and M-SAN products, while Kerry/c-LEcta continues to compete with EU GMP-grade Denarase offerings.

Asia-Pacific holds a 23.0% market share, valued at approximately USD 0.097 billion in 2025, and is projected to reach USD 0.238 billion by 2032, expanding at the fastest regional CAGR of 13.7%. Growth is driven by rising regenerative medicine approvals and expanding biomanufacturing capacity. Japan’s PMDA supports dedicated regenerative therapy pathways, while companies like GenScript are scaling GMP enzyme production. Growth in the region is closely tied to expanding viral vector manufacturing and alignment with global regulatory standards.

Latin America accounts for 4.0% of the market, valued at approximately USD 0.017 billion in 2025, and is projected to reach USD 0.029 billion by 2032, growing at a CAGR of 8.0%. The region’s demand is primarily driven by vaccine production, academic research, and gradual expansion of biopharmaceutical manufacturing capabilities, with increasing adoption of nucleases in downstream processing workflows.

 

Market Direction: From Commodity Enzyme to Integrated Process Platform

The market is shifting from selling enzyme units to selling validated process performance. Suppliers now compete on salt tolerance, activity under real manufacturing conditions, GMP-grade production, regulatory support (DMFs), and compatibility with CDMO workflows. For example, companies like ArcticZymes and c-LEcta have expanded GMP nuclease offerings with regulatory filings and process-specific enzymes designed for viral vector production.

Adoption is limited by process lock-in and lack of standardisation in enzyme activity units, making cross-supplier comparison difficult. Performance also varies with salt, pH, temperature, and DNA load, meaning a cheaper enzyme can increase total costs if it requires re-optimisation or revalidation of downstream steps.

Once a nuclease is embedded in a clinical or commercial vector process, switching suppliers often requires new impurity, stability, and comparability studies, increasing regulatory burden. As a result, established suppliers with proven regulatory history and DMFs hold an advantage.

 

Non-specific Endonuclease Market Report Coverage Table

 

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.42 Billion
Revenue Forecast in 2032	USD 0.82 Billion
Overall Growth Rate	CAGR of 10.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Grade, By Product Type, By Form, By Application, By End User, By Geography
By Grade	Research Grade, GMP Grade
By Product Type	Standard Non-specific Endonucleases, Salt-Tolerant Non-specific Endonucleases
By Form	Liquid, Lyophilized
By Application	Viral Vector Manufacturing, Vaccine Manufacturing, Recombinant Protein and Biologics Production, Cell and Gene Therapy Manufacturing, Research and Cell Lysis
By End User	Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations (CDMOs/CMOs), Academic and Research Institutes, Diagnostic and Clinical Laboratories
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Singapore, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising adoption of GMP-grade ancillary materials in advanced biomanufacturing, expanding viral-vector and cell & gene therapy production, increasing regulatory focus on residual DNA control, growing demand for salt-tolerant and process-specific nucleases
Customization Option	Available upon request